Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for Airway Responsiveness in Poorly Controlled Asthma
NCT00133042Phase 4Completed
- Sponsor
- University of Florida
- Start
- Dec 2004
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in asthma comparing Omalizumab with Placebo (2 arms). Primary endpoint: Provocative concentration of adenosine 5' monophosphate causing a 20% fall in FEV1 at 4 months. Started Dec 2004; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00133042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133042.